1642

Patent Docket P1793R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

200

In re Application of

Laura C. Simmons et al.

Serial No.: 10/020,786

Commissioner for Patents

Alexandria, VA 22313-1450

P.O. Box 1450

Filed: December 13, 2001

For: PROKARYOTICALLY PRODUCED

ANTIBODIES AND USES THEREOF

Group Art Unit: 1642

Examiner: Larry R. Helms

CERTIFICATE OF MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

June 24 2003

June <u>27</u>, 200: //

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

JUN 2 7 2003

TECH CENTER 1600/2900

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[] 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as

checked below.

[] 37 CFR §1.97(d)

• after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR $\S 1.97(c)$ or 37 CFR $\S 1.97(d)$ is checked above, the following statement under 37 CFR $\S 1.97(e)$ may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filling of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filling of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith. A copy of the international search report for the corresponding PCT application is enclosed herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No., filed and relied upon in this application for an earlier filing date under 35 USC § 120.

A concise explanation	of relevance of the items	listed on PTO-1449 is:
-----------------------	---------------------------	------------------------

- [x] not given
- [] given for each listed item
- [] given for only non-English language listed item(s) [Required]

10/020,786

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR $\S 1.97(g)$, the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Date: June ____, 2003

Respectfully submitted,

GENENTECH, INC.

Payl Naik, Ph.D.

Reģ. No. 49,075 Telephone No. (650) 225-5530

09157

PATENT TRADEMARK OFFICE

FORM PTO-1449 JUN 2 6 2003 LIST OF DISCLOSURES CH PPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No. P1793R1

Serial No. 10/020,786

Applicant

Laura C. Simmons et al.

Filing Date

Group

 					13 Dec 200	'¹	1642		
				U.S. PATENT DOCUMENTS					
Examiner				T		7			
Initials		Document Number	Date	Name	Class	Subcla	ıss	Filing	Date
	86	5,747,662	05.05.98	Simmons et al.				9 - 4.0	
				FOREIGN PATENT DOCUMENT	rs				
Examiner Initials		Document Number	Date	Country	Class	Subcla	ss	Transla Yes	ation No
]	87	0 731 167	11.09.96	EP			-		
-	88	WO 93/08300	29.04.93	PCT					
	89	WO 93/19196	30.09.93	PCT					
			OTHER DISCI	LOSURES (Including Author, Title, Date	Pertinent Pages et	to)		1	
	90	Boyd et al., "The Functional Activi	Effect of the	Removal of Sialic Acid, Galacto -1H." Molecular Immunology 32:13:	2 2 2 3 80 3 3 8	rbohydra	te on	the	
	91	Schmiedl et al. A	ntibody Engine	eering, Berlin Heidelberg:Springe	er pps. 257 (200	1)			
	92	Simmons, L. et al production of agl	., "Expression	of full-length immunoglobins in	Escerichia col	i: Rapid	and e	fficie	nt

production of aglycosylated antibodies" <u>Journal of Immunological Methods</u> 263:133-147 (2002)

RECEIVE	
HLU-	

JUN 2 7 2003

TECH CENTER 1600/2900

Examine	r	Date Considered
		Date Considered
*Examin	er: Initi	al if reference considered whether or not citation is in /
if not i	n confo	al if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.